Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Srivatsan Raghavan, M.D.,Ph.D.

Co-Author

This page shows the publications co-authored by Srivatsan Raghavan and Gad Getz.
Connection Strength

0.149
  1. TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma. Cancer Discov. 2019 08; 9(8):1064-1079.
    View in: PubMed
    Score: 0.051
  2. WRN helicase is a synthetic lethal target in microsatellite unstable cancers. Nature. 2019 04; 568(7753):551-556.
    View in: PubMed
    Score: 0.051
  3. Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine. Cancer Discov. 2018 09; 8(9):1096-1111.
    View in: PubMed
    Score: 0.048
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.